<DOC>
	<DOCNO>NCT00002994</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill solid tumor cell . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Pilot study examine effectiveness interleukin-2 plus monoclonal antibody treat patient solid tumor .</brief_summary>
	<brief_title>Interleukin-2 Plus Monoclonal Antibody Therapy Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect humanize anti-HER2 monoclonal antibody administer combination interleukin-2 ( IL-2 ) patient solid tumor . II . Measure vitro cytotoxicity use peripheral blood mononuclear cell , plasma , target cell line express HER2 patient population . III . Phenotypically characterize effector cell time antibody administration 24 hour three day intermediate dose IL-2 pulsing patient . IV . Measure antitumor response patient . OUTLINE : Cohorts 6 patient enrol 4 antibody dose level . After least 6 patient treat study least 30 day , next dose level may initiate provide few 2 first 6 evaluable patient experience dose limit toxicity ( DLT ) relate either antibody combination antibody interleukin-2 ( IL-2 ) . If 2 patient experience DLT , next cohort enrol antibody dose midway current previous dose level . An additional 6 patient enter maximum tolerated dose . On course 1 , patient receive IL-2 subcutaneously ( SQ ) daily day 1-7 humanized anti-HER-2 monoclonal antibody IV 90 minute day 7 . Patients receive intermediate dose pulse IL-2 SQ day 8-10 low dose IL-2 SQ day 11-20 . On course 2 subsequent course , patient receive humanize anti-HER2 monoclonal antibody IV immediately prior IL-2 ( SQ ) day 1 intermediate dose pulse IL-2 ( SQ ) day 1-3 . Patients receive low dose IL-2 ( SQ ) day 4-14 . Treatment may delay 7 day allow recovery tumor restaging , daily low dose IL-2 continue interval . Patients follow 4 week every 8 week progression death . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonhematologic malignancy Refractory disease disease effective standard therapy exist HER2 overexpression tumor tissue Measurable evaluable disease No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : CALGB 01 Life expectancy : At least 3 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 5 time normal Alkaline phosphatase great 5 time normal Renal : BUN great 1.5 time normal Creatinine great 1.5 time normal Cardiovascular : No uncontrolled severe cardiac disease LVEF least 45 % MUGA echocardiogram Other : HIV negative No immunologic disease ( e.g. , autoimmune disease ) Negative viral hepatitis antibodies No psychiatric condition would prevent compliance treatment Not pregnant nursing Fertile patient must use effective contraception No active uncontrolled bacterial , viral , fungal infection Prior concurrent malignancy allow PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interleukin2 ( IL2 ) and/or herceptin allow No concurrent immunosuppressive drug immunomodulators ( IL2 ) Chemotherapy : At least 6 week since nitrosoureas , melphalan , mitomycin More 4 week since chemotherapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : More 4 week since prior radiotherapy Surgery : At least 4 week since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>